Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
In our urban HIV clinic, 63% of PWH were eligible for LAI cabotegravir/rilpivirine, and 15% initiated it within 2.5 years post-approval. Age and provider patterns significantly influenced LAI cabotegravir/rilpivirine uptake. Understanding factors driving LAI cabotegravir/rilpivirine uptake is key to expanding its reach.
Authors
- Moira McNulty (ORCID: https://orcid.org/0000-0002-9651-254X)
- Alicia Dawdani
- Geoffroy Liégeon (ORCID: https://orcid.org/0000-0003-1267-4347)
- Eleanor E. Friedman (ORCID: https://orcid.org/0000-0001-5840-9763)
- Paul Djuricich
- Sophie Plotkin
- Christopher Kaperak
- J. Schneider (ORCID: https://orcid.org/0009-0003-0553-3447)
- Aniruddha Hazra (ORCID: https://orcid.org/0000-0001-8557-4465)
- Jessica Schmitt (ORCID: https://orcid.org/0000-0001-5125-7808)
- Katerina A. Christopoulos (ORCID: https://orcid.org/0000-0002-8598-2191)
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- University of Chicago (US)
- University of San Francisco (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1093/jac/dkaf346
- Primary Topic
- HIV, Drug Use, Sexual Risk
- Type
- article
- Field-Weighted Citation Impact
- 0.00